From this perspective, therapeutic approaches making the anti-apoptotic pathway activated, such as inhibition of BCL2, might confer reversal of drug-resistance and further improve survival outcomes of patients with DLBCL treated with R-CHOP. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.